Aktie A3H210 AAP IMPLANTATE AG
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen aap Implantate AG

Aktien

A3H210

DE000A3H2101

AAQ1

Markt geschlossen - Xetra
Andere Börsenplätze
 17:36:07 24.05.2024 		% 5 Tage % 1. Jan.
1,15 EUR -2,54 % Intraday Chart für aap Implantate AG -17,27 % +38,55 %
2021 Aap Implantate Ag meldet Ergebnis für das Geschäftsjahr zum 31. Dezember 2020 CI
2021 Aap Implantate AG gibt Ergebnisprognose für das Jahr 2021 ab CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
Aap Implantate AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Aap closes Q1 2024 with sales growth of 5.6% and positive developments at all operating levels and makes a strong start to Q2 2024
NVR: aap Implantate AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Aap successfully places a 10% capital increase from authorized capital at EUR 1.10 with exclusion of subscription rights
Aap Implantate AG: aap postpones publication of the consolidated financial statements 2023 due to staff shortages
Aap 100% approval of the proposed resolution to amend the terms and conditions of the mandatory convertible bond 2023/2028
Aap Implantate AG: Capital increase from authorized capital with exclusion of subscription rights
Aap proposes to the bondholders of the mandatory convertible bond 2023/2028 an amendment to the bond terms and conditions to enable the bondholders to exercise their conversion rights earlier
After a mixed 2023 financial year, aap makes a strong start to the 2024 financial year
Aap Implantate : with positive EBITDA in Q2 and H1/2021 for first time since focusing on trauma and significant sales growth of +74% (Q2) and +37% (H1)
Aap Implantate : with positive EBITDA in Q2 and H1/2021 for first time since focusing on trauma and significant sales growth of +74% (Q2) and +37% (H1)
Aap Implantate AG Announces Sales Results for the Second Quarter and Half Year Ended 30 June 2021
Q1/21: Successful start to the year with sales growth (+9%) and significant earnings improvement (+91%) despite still burdening COVID-19 pandemic - restructuring successes clearly visible
Aap Implantate Ag Reports Earnings Results for the Full Year Ended December 31, 2020
2020 financial statements: visible results under restructuring with significantly improved Recurring EBITDA (+28%) in challenging times of COVID-19 pandemic
Aap Implantate AG Provides Earnings Guidance for the Year 2021
Q1/2021: Solid start to year with 9% sales growth despite still burdening COVID 19 pandemic; more than 500 surgeries in US mark new high; Q2 order book well filled
Aap Implantate AG Announces Sales Results for the First Quarter of 2021
Aap Implantate AG Provides Sales Guidance for the Second Quarter of 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3H210 Aktie
  4. Nachrichten aap Implantate AG
  5. Andere Sprachen